Soligenix Inc. (SNGX) Reports Promising HyBryte Progress in CTCL Treatment
TL;DR
Soligenix's HyBryte(TM) shows a 75% success rate in early-stage CTCL treatment, offering a competitive edge in biopharmaceutical innovations for rare diseases.
HyBryte(TM) treatment for CTCL demonstrated 75% efficacy at 18 weeks, with safety and tolerability confirmed in an ongoing open-label study mirroring the FLASH2 trial design.
HyBryte(TM) provides a safer, faster-acting treatment for CTCL, improving patient outcomes and addressing the urgent need for new therapies in this underserved area.
Discover how Soligenix's HyBryte(TM) is revolutionizing CTCL treatment with an 85% improvement rate, offering hope through its non-mutagenic mechanism and rapid response.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (SNGX) has shared encouraging interim data from a study on HyBryte(TM), a treatment for early-stage cutaneous T-cell lymphoma (CTCL), in a recent podcast by the Cutaneous Lymphoma Foundation. Dr. Ellen Kim, the study's Principal Investigator, reported a 75% treatment success rate at 18 weeks, with improvements up to 85% in patients treated through 54 weeks. This study, mirroring the design of the ongoing FLASH2 confirmatory trial, underscores HyBryte's safety and tolerability, with no serious side effects noted.
The open-label study's design, which eliminates rest periods and extends treatment duration, aims to reflect real-world clinical practice, potentially enhancing efficacy. Dr. Kim highlighted the limitations of current skin-directed therapies and the critical need for new treatment options for early-stage CTCL. HyBryte, with its non-mutagenic mechanism and rapid response, presents a promising alternative to traditional treatments such as steroids, chemotherapy, and phototherapy.
This development is significant for the CTCL community, as it addresses an unmet medical need for safer and more effective treatments. The positive interim results from the study not only bolster the case for HyBryte's potential regulatory approval but also offer hope to patients battling this chronic and underserved form of cancer. The ongoing FLASH2 trial's enrollment further emphasizes the medical community's interest in validating HyBryte's efficacy and safety profile.
Curated from InvestorBrandNetwork (IBN)
